Endoscopic management of vesicoureteral reflux: does it stand the test of time?
Endoscopic subureteral injection of tissue-augmenting substances, a 15-minute outpatient procedure has become an alternative to long-term antibiotic prophylaxis and surgical intervention in the treatment of vesicoureteral reflux (VUR) in children. This paper reviews the long-term results of endoscopic treatment of reflux using various tissue-augmenting substances presently available. In terms of effectiveness and long-term successful results, polytetrafluoroethylene is still the most reliable injectable material for the endoscopic treatment of VUR.
Chertin
Boris
B
Children's Research Centre, Our Lady's Hospital for Sick Children, University College Dublin, Dublin, Ireland
Puri
Prem
P
D001672:Biocompatible Materials; D019902:Chondrocytes / Q000637:transplantation; D003094:Collagen; D003558:Cystoscopy; D003911:Dextrans; D004129:Dimethylpolysiloxanes; D006801:Humans; D006820:Hyaluronic Acid; D007267:Injections / Q000379:methods; D011138:Polytetrafluoroethylene; D012828:Silicones; D013997:Time Factors; D018666:Ureteroscopy; D014718:Vesico-Ureteral Reflux / Q000628:therapy*
D001672:Biocompatible Materials; D003911:Dextrans; D004129:Dimethylpolysiloxanes; D012828:Silicones; C094535:deflux; C048470:glutaraldehyde-cross-linked collagen; C013830:baysilon; D011138:Polytetrafluoroethylene; D006820:Hyaluronic Acid; D003094:Collagen